Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities

This study is evaluating a specialized bone graft material that releases antibiotics at the site of an infected knee replacement (TKA) to help treat the infection while also supporting new bone growth. It is designed for patients whose knee implant has become infected. You may be eligible if... - You are at least 22 years old - You have a confirmed infected total knee replacement (TKA) - You have adequate soft tissue covering the knee area - Your life expectancy is at least 1 year - You are willing and able to attend follow-up visits and follow the medication schedule You may NOT be eligible if... - You have severe kidney impairment (eGFR below 50) or are on dialysis - You have a known allergy to aminoglycoside antibiotics or calcium hydroxyapatite - You have a calcium metabolism disorder - You have uncontrolled diabetes (HbA1c above 8) - You have a bone disease such as Paget's disease, renal osteodystrophy, or osteogenesis imperfecta - You have a neuromuscular disorder such as myasthenia gravis - You have an untreated malignancy or are undergoing chemotherapy or radiation - Your leg has inadequate blood flow or nerve supply that could impair healing - You are HIV positive - You are pregnant Talk to your doctor to see if this trial is right for you.